USFDA approval for Ranbaxy drug

New Delhi: Ranbaxy Laboratories Ltd has received approval from the US Food and Drug Administration to commercialise minocycline hydrochloride tablets, an antibiotic used to treat bacterial infections.

The product will be marketed exclusively by Florida-based Stiefel Laboratories Inc. Said Mr Dipak Chattaraj, President, Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of Ranbaxy, "Efforts to provide an alternate dosage form to Stiefel's product portfolio utilising Ranbaxy's technical skills demonstrates synergy between the two companies that has been gained through this strategic alliance."

Mr Charles W. Stiefel, Chairman, President and CEO of Stiefel Laboratories, added in a statement, "This is a co-operative effort between Stiefel and Ranbaxy that is mutually beneficial to both organisations and of value to prescribers and patients."